132 related articles for article (PubMed ID: 1725149)
1. Direct and indirect pathogenicity of beta-lactamase-producing bacteria in respiratory tract infection in children. Role of cephalosporins resistant to enzymatic hydrolysis.
Stefani S; Pellegrino MB; Russo G; Nicoletti G
Drugs; 1991; 42 Suppl 4():14-8. PubMed ID: 1725149
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect pathogenicity of beta-lactamase-producing bacteria in mixed infections in children.
Brook I
Crit Rev Microbiol; 1989; 16(3):161-80. PubMed ID: 2644068
[TBL] [Abstract][Full Text] [Related]
3. The concept of indirect pathogenicity by beta-lactamase production, especially in ear, nose and throat infection.
Brook I
J Antimicrob Chemother; 1989 Nov; 24 Suppl B():63-72. PubMed ID: 2691486
[TBL] [Abstract][Full Text] [Related]
4. The role of beta-lactamase-producing bacteria in respiratory tract infections.
Brook I
Scand J Infect Dis Suppl; 1988; 57():41-9. PubMed ID: 3074471
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect pathogenicity of anaerobic bacteria in respiratory tract infections in children.
Brook I
Adv Pediatr; 1987; 34():357-77. PubMed ID: 3318301
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
[TBL] [Abstract][Full Text] [Related]
7. Role of anaerobic beta-lactamase-producing bacteria in upper respiratory tract infections.
Brook I
Pediatr Infect Dis J; 1987 Mar; 6(3):310-6. PubMed ID: 3554127
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.
Dornbusch K; Kronvall G; Göransson E; Mörtsell E
J Antimicrob Chemother; 1989 Mar; 23 Suppl C():31-41. PubMed ID: 2786517
[TBL] [Abstract][Full Text] [Related]
9. The threat of resistance to the new oral cephalosporins.
Cullmann W
Chemotherapy; 1992; 38 Suppl 2():10-7. PubMed ID: 1516458
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
11. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
Schito GC; Pesce A; Debbia EA
Drugs; 1994; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
[TBL] [Abstract][Full Text] [Related]
12. Recovery of beta-lactamase producing bacteria in pediatric infections.
Brook I
Can J Microbiol; 1987 Oct; 33(10):888-95. PubMed ID: 3121158
[TBL] [Abstract][Full Text] [Related]
13. Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.
Neu HC
Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S88-92. PubMed ID: 7567316
[TBL] [Abstract][Full Text] [Related]
14. Importance of beta-lactamase stability in treating today's respiratory tract infections.
Cullmann W
Respiration; 1993; 60 Suppl 1():10-5. PubMed ID: 8386847
[TBL] [Abstract][Full Text] [Related]
15. Emergence and persistence of beta-lactamase-producing bacteria in the oropharynx following penicillin treatment.
Brook I
Arch Otolaryngol Head Neck Surg; 1988 Jun; 114(6):667-70. PubMed ID: 3130087
[TBL] [Abstract][Full Text] [Related]
16. Microbiology of common infections in the upper respiratory tract.
Brook I
Prim Care; 1998 Sep; 25(3):633-48. PubMed ID: 9673324
[TBL] [Abstract][Full Text] [Related]
17. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: General view of the pathogens' antibacterial susceptibility.
Yanagihara K; Watanabe A; Aoki N; Matsumoto T; Yoshida M; Sato J; Wakamura T; Sunakawa K; Kadota J; Kiyota H; Iwata S; Kaku M; Hanaki H; Ohsaki Y; Fujiuchi S; Takahashi M; Takeuchi K; Takeda H; Ikeda H; Miki M; Nakanowatari S; Takahashi H; Utagawa M; Nishiya H; Kawakami S; Morino E; Takasaki J; Mezaki K; Chonabayashi N; Tanaka C; Sugiura H; Goto H; Saraya T; Kurai D; Katono Y; Inose R; Niki Y; Takuma T; Kudo M; Ehara S; Sato Y; Tsukada H; Watabe N; Honma Y; Mikamo H; Yamagishi Y; Nakamura A; Ohashi M; Seki M; Hamaguchi S; Toyokawa M; Fujikawa Y; Mitsuno N; Ukimura A; Miyara T; Nakamura T; Mikasa K; Kasahara K; Ui K; Fukuda S; Nakamura A; Morimura M; Yamashita M; Takesue Y; Wada Y; Sugimoto K; Kusano N; Nose M; Mihara E; Kuwabara M; Doi M; Watanabe Y; Tokuyasu H; Hino S; Negayama K; Mukae H; Kawanami T; Ota T; Fujita M; Honda J; Hiramatsu K; Aoki Y; Fukuoka M; Magarifuchi H; Nagasawa Z; Kaku N; Fujita J; Higa F; Tateyama M
J Infect Chemother; 2017 Sep; 23(9):587-597. PubMed ID: 28669567
[TBL] [Abstract][Full Text] [Related]
18. In vitro investigation of the indirect pathogenicity of beta-lactamase-producing microorganisms in the nasopharyngeal microflora.
Kaieda S; Yano H; Okitsu N; Hosaka Y; Okamoto R; Inoue M; Takahashi H
Int J Pediatr Otorhinolaryngol; 2005 Apr; 69(4):479-85. PubMed ID: 15763284
[TBL] [Abstract][Full Text] [Related]
19. Moraxella (Branhamella) catarrhalis--clinical and molecular aspects of a rediscovered pathogen.
Enright MC; McKenzie H
J Med Microbiol; 1997 May; 46(5):360-71. PubMed ID: 9152030
[TBL] [Abstract][Full Text] [Related]
20. [Antimicrobial activities of sultamicillin against clinical isolates from upper respiratory tract infections].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
Jpn J Antibiot; 1988 Sep; 41(9):1194-204. PubMed ID: 3266508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
